These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31126617)

  • 1. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Awasthi U; Grover R; Varshney A; Videkar C
    Am J Ophthalmol; 2019 Jul; 203():121. PubMed ID: 31126617
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
    Am J Ophthalmol; 2019 May; 201():86-87. PubMed ID: 30616898
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictive Factors of Response to Mineralocorticoid Receptor Antagonist in Nonresolving Central Serous Chorioretinopathy.
    Călugăru D; Călugăru M
    Am J Ophthalmol; 2019 May; 201():87-88. PubMed ID: 30683307
    [No Abstract]   [Full Text] [Related]  

  • 4. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
    Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F
    Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
    Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
    Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
    Yang D; Eliott D
    Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
    Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists].
    Cakir B; Agostini H; Lange C
    Ophthalmologe; 2019 Feb; 116(2):189-200. PubMed ID: 30255262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
    Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
    Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
    Sanhueza A; González R
    Medwave; 2020 Sep; 20(8):e8036. PubMed ID: 33017387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
    Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
    Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
    [No Abstract]   [Full Text] [Related]  

  • 12. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
    Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG
    Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
    Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
    Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
    Kapoor KG; Wagner AL
    Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence.
    Bousquet E; Zhao M; Daruich A; Behar-Cohen F
    Exp Eye Res; 2019 Oct; 187():107754. PubMed ID: 31401003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy Rationale for Mineralocorticoid-Receptor Antagonists, Acetazolamide and a Switch of Therapy in Nonresponders in Central Serous Chorioretinopathy.
    Rübsam A; Thieme CE; Schlomberg J; Winterhalter S; Müller B; Joussen AM; Stübiger N
    J Ocul Pharmacol Ther; 2017 Apr; 33(3):141-148. PubMed ID: 28277988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy.
    Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q
    Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy].
    Maier M; Stumpfe S; Feucht N; Strobl P; Rath V; Lohmann CP
    Ophthalmologe; 2014 Feb; 111(2):173-80. PubMed ID: 24510173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor inhibitor for long-standing central serous chorioretinopathy.
    Suzuki A; Takano Y; Ando Y; Ogawa J; Ishida M; Baba A; Imamura Y
    Acta Ophthalmol; 2018 Aug; 96(5):e662-e663. PubMed ID: 29671951
    [No Abstract]   [Full Text] [Related]  

  • 20. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
    Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
    J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.